# Advent Life Sciences Growth Fund

> Separate life-sciences growth vehicle focused chiefly on UK clinical development and commercial scale-up. British Business Bank committed approximately €87.2M on September 24, 2026. It lists a fundraising target of approximately €233M–€349M, not a verified first/final close or completed fund size.

## Profile

- **Stage-based planning range:** $1M–$10M
- **Check-size evidence basis:** estimated
- **Founded:** N/A
- **Headquarters:** London, UK
- **AUM:** N/A
- **Rounds they lead:** N/A
- **Rounds they invest:** Series B, Series B+, Series C, Growth

## Links

- [Website](https://adventls.com/)

## In-depth investment analysis

## Mandate
Advent's distinct growth vehicle targets later clinical-stage healthcare companies and nontherapeutic products with initial commercial traction, primarily in the UK. This differs from [Fund IV](/fund/advent-life-sciences-fund-iv)'s early-stage mandate.

## Disclosed commitments vs fund size
On September 24, British Business Bank [confirmed its commitment](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-agrees-commit-ps135m-two-new-advent-life-sciences-funds) equivalent to approximately **€87.2M** at the contemporaneous ECB fixing. Its [vehicle page](https://www.british-business-bank.co.uk/venture-link/advent-life-sciences-growth-fund) gives a **€233M–€349M fundraising target**, not an amount already closed. No confirmed GP first/final close date, completed fund amount, other LP roster or fee/carry schedule has been published in these primary documents.

## Practical founder tour
An illustrative clinical-stage founder would present trial endpoints, recruitment and risk, regulatory plan, runway to readout and manufacturing requirements. For nontherapeutic products, validation includes actual paying customers, sales economics and reimbursement where relevant. The public strategy does not specify minimum check size or guaranteed funding process.

Related [Advent Life Sciences](/fund/advent-life-sciences); [Fund IV](/fund/advent-life-sciences-fund-iv). Sources: [Bank statement](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-agrees-commit-ps135m-two-new-advent-life-sciences-funds); [Growth Fund listing](https://www.british-business-bank.co.uk/venture-link/advent-life-sciences-growth-fund); [ECB](https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/index.en.html).

## Research sources

- [Growth Fund target & commitment](https://www.british-business-bank.co.uk/venture-link/advent-life-sciences-growth-fund)
- [LP announcement](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-agrees-commit-ps135m-two-new-advent-life-sciences-funds)
- [FX source](https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/index.en.html)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/fund/advent-life-sciences-growth-fund